Showing 1 - 10 of 10
Persistent link: https://www.econbiz.de/10003546677
We analyze how a manufacturer with a brand-name drug close to patent expiration decides to launch a product-line extension (an upgrade through innovation) before it faces generic competition. There are two types of physicians: loyal physicians always prescribe first the product-line extension...
Persistent link: https://www.econbiz.de/10009355566
Persistent link: https://www.econbiz.de/10011483931
Persistent link: https://www.econbiz.de/10009300521
Background: Antibiotics have been overprescribed to treat infectious diseases and have generated antimicrobial resistances that reduce their effectiveness. Following the rationale behind the new paradigm of personalized medicine, point-of-care diagnostic testing (POCT) has been proposed to...
Persistent link: https://www.econbiz.de/10012607268
Persistent link: https://www.econbiz.de/10010207164
Although personalized medicine is becoming the new paradigm to manage some diseases, the economics of personalized medicine have only focused on assessing the efficiency of specific treatments, lacking a theoretical framework analyzing the interactions between pharmaceutical firms and healthcare...
Persistent link: https://www.econbiz.de/10011586604
Persistent link: https://www.econbiz.de/10011814176
Background: Currently, personalised medicine is becoming more frequently used and many drug companies are including this strategy to gain market access for very specialized therapies. In this article, in order to understand the relationships between the health authority and the drug company when...
Persistent link: https://www.econbiz.de/10012162381
Persistent link: https://www.econbiz.de/10014328079